PMLiVE6d
Pfizer shares positive phase 3 results for Talzenna combination in prostate cancer
Up to 20% of patients will develop metastatic castration-resistant disease within five to seven years of diagnosis ...
PMLiVE5d
Merck and Exelixis partner to evaluate new cancer combination treatments
Merck & Co – known as MSD outside the US and Canada – and Exelixis have entered into a clinical development collaboration to ...
PMLiVE10d
Astellas and AviadoBio enter exclusive dementia gene therapy deal worth over $2bn
Astellas Pharma and AviadoBio have entered into an exclusive option and licence agreement worth over $2bn for an ...
PMLiVE12d
J&J’s Erleada shows overall survival benefit in head-to-head prostate cancer study
Johnson & Johnson (J&J) has announced results from a real-world study comparing its Erleada (apalutamide) to Pfizer and ...
PMLiVE9d
Merck and Astellas/Pfizer’s bladder cancer combination receives MHRA approval
Merck & Co’s – known as MSD outside the US and Canada – Keytruda (pembrolizumab) and Astellas/Pfizer’s Padcev (enfortumab vedotin) have been approved by the Medicines and Healthcare products ...
PMLiVE11d
Merck’s Keytruda shows promise as perioperative head and neck cancer treatment
Merck & Co – known as MSD outside the US and Canada – has shared positive results from a late-stage study of its anti-PD-1 therapy in head and neck cancer. The phase 3 KEYNOTE-689 trial has been ...
PMLiVE9d
Roche’s Itovebi combination granted FDA approval for advanced breast cancer
Roche’s PI3K inhibitor Itovebi (inavolisib) has been approved by the US Food and Drug Administration (FDA) as part of a combination treatment for advanced breast cancer. The drug has been authorised ...
PMLiVE16d
Researchers develop new approach to target cells affected by motor neurone disease
It is hoped that preventing healthy cells from reading the molecules’ messages could lead to safer and more effective gene therapies for MND, as well as other neurodegenerative diseases, including ...
PMLiVE13d
AbbVie shares promising late-stage results for Parkinson’s disease candidate tavapadon
AbbVie has shared positive top-line results from a late-stage study of its investigational Parkinson’s disease (PD) drug in adults. The phase 3 TEMPO-1 trial evaluated two fixed doses of the D1/D5 ...
PMLiVE18d
Bristol Myers Squibb announces positive data for Sotyktu in moderate-to-severe psoriasis
Bristol Myers Squibb (BMS) has announced positive results from a phase 3b/4 study of its oral TYK2 inhibitor Sotyktu (deucravacitinib) in moderate-to-severe scalp psoriasis. Data from the ongoing ...
PMLiVE11d
Ipsen’s Iqirvo approved by MHRA to treat primary biliary cholangitis in adults
Ipsen’s Iqirvo (elafibranor) has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with primary biliary cholangitis (PBC). The oral peroxisome ...
PMLiVE10d
GSK’s RSV vaccine Arexvy shown to protect older adults across three seasons
GSK’s Arexvy has been shown to protect older adults against respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD) over three full RSV seasons. Results from the phase 3 ...